Neonatal lupus and IUGR following alpha-interferon therapy during pregnancy

J Perinatol. 2005 Aug;25(8):552-4. doi: 10.1038/sj.jp.7211342.

Abstract

Interferon alfa-2a is a cytokine produced by recombinant DNA techniques and has antiproliferative, antiviral and immunomodulating effects. A number of case reports in the past have suggested relative safety of alpha-interferons during pregnancy with little or no effect on the fetus. A 15-year-old adolescent became pregnant while receiving alpha-interferon for essential thrombocythemia. She delivered a small-for-gestational age baby girl at 33 weeks gestation. The infant displayed a facial rash characteristic of neonatal lupus and transient thrombocytopenia; maternal and neonatal serologies were typical for drug-induced lupus. These findings suggest probable association between maternal use of alpha interferon and adverse effects in the fetus.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Female
  • Fetal Growth Retardation / chemically induced*
  • Humans
  • Infant, Newborn
  • Infant, Newborn, Diseases / chemically induced*
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / therapeutic use
  • Lupus Erythematosus, Cutaneous / chemically induced*
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Thrombocythemia, Essential / drug therapy*

Substances

  • Interferon-alpha